Skip to main content
PMC home page
Cell Death & Disease logoLink to Cell Death & Disease
. 2020 Nov 30;11(11):1021. doi: 10.1038/s41419-020-03225-y

BRDT promotes ovarian cancer cell growth

Ling Chen 1,#, Shang Cai 2,#, Jing-mei Wang 1, Ying-ying Huai 3, Pei-Hua Lu 4,✉, Qian Chu 3,✉
PMCID: PMC7705741  PMID: 33257688

Abstract

Bromodomain testis-specific factor (BRDT) is a member of the bromodomain and extra-terminal (BET) family proteins. Its expression and potential functions in ovarian cancer were examined. We show that BRDT is overexpressed in human ovarian cancer tissues and in established (CaOV3)/primary ovarian cancer cells. However, its expression is low in ovarian epithelial tissues and cells. Significantly, shRNA-induced silencing or CRISPR/Cas9-mediated knockout of BRDT inhibited ovarian cancer cell growth, viability, proliferation and migration, and induced significant apoptosis activation. Conversely, exogenous overexpression of BRDT, by a lentiviral construct, augmented CaOV3 cell proliferation and migration. In CaOV3 cells expression of two key BRDT target genes, polo-like kinase 1 (PLK1) and aurora kinase C (AURKC), was downregulated by BRDT shRNA or knockout, but upregulated with BRDT overexpression. In vivo, xenograft tumors-derived from BRDT-knockout CaOV3 cells grew significantly slower than control tumors in severe combined immunodeficient (SCID) mice. Furthermore, intratumoral injection of BRDT shRNA lentivirus potently inhibited the growth of primary ovarian cancer xenografts in SCID mice. Downregulation of PLK1 and AURKC was detected in BRDT-knockout and BRDT-silenced tumor tissues. Collectively, BRDT overexpression promotes ovarian cancer cell progression. Targeting BRDT could be a novel strategy to treat ovarian cancer.

Subject terms: Oncogenes, Ovarian cancer

Introduction

Despite significant progresses have been achieved to improve the overall survival of ovarian cancer in past decades, it is still one primary cause of female mortality1. In the United States alone, the American Cancer Society estimates 22,440 new cases of ovarian cancer and 14,080 related deaths each year2. Ovarian cancer is typically diagnosed at late stages, due to the lack of effective screening strategy3–5. Standard treatments for newly diagnosed ovarian cancers include surgery and platinum-based chemotherapy3–5. Yet, because of the significant resistance and recurrence, researchers are focusing on novel oncogenes and cell signaling pathways essential for cancer progression3–5.

Bromodomain testis-specific factor (BRDT) is a member of the bromodomain and extra-terminal (BET) family proteins6. BRDT, like other BET family proteins (BRD1–4), epigenetically regulates targeted genes expression through interacting with acetylated lysines7,8, critical for normal development and disease (cancer) progression6. Recent studies have implied that BET family proteins are key oncogenic proteins, being overexpressed in a number of different cancers7,8. Inhibitors of BET proteins have displayed promising efficiency against human cancer cells in vitro and in vivo9,10.

BRDT is expressed in testes, regulating the meiotic and post-meiotic genes expression to promote spermatogenesis11. Cancer cells have the ability to reactivate the normally silent testis-restricted genes, which are important for cancer progression6. Recent studies have shown that BRDT is ectopically activated and expressed in human cancers6. It has been proposed that BRDT could be a novel biomarker and a possible therapeutic target for human cancer6. Several BRDT-regulated genes, including polo-like kinase 1 (PLK1)12 and aurora kinase C (AURKC)13, are key oncogenic proteins6,11. BRDT expression and potential functions in ovarian cancer have not been studied thus far.

Materials and methods

Chemicals and reagents

Cell culture reagents were provided by Gibco Co. (Grand Island, NY). Puromycin, polybrene and other reagents were obtained from Sigma-Aldrich (St. Louis, Mo). All primers, sequences and viral constructs were provided by Shanghai Genechem Co (Shanghai, China). The anti-BRDT antibody was purchased from Sigma-Aldrich (SAB2106423). Antibodies for cleaved-caspase-3 (#9664), cleaved-poly (ADP-ribose) polymerase (PARP) (#5625), cleaved-caspase-9 (#20750), Tubulin (#2125) and PLK1 (#4513) were obtained from Cell Signaling Tech China (Shanghai, China). The anti-AURKC antibody was obtained from Abcam (ab46783). The reagents for RNA assays were provided by Thermo-Fisher Invitrogen (Suzhou, China).

Human tissues

From a total of six (6) primary ovarian cancer patients, the fresh human ovarian cancer tissues (“Ca”) and para-cancer ovarian epithelial tissues (“S”) were acquired. Tissues were washed, minced, and homogenized in the tissue lysis buffer (Beyotime Biotechnology, Shanghai, China), stored in liquid nitrogen. Expression of BRDT was tested by quantitative reverse transcriptase PCR (“qPCR”) and western blotting assays. The written-informed consent was obtained from each participant. The enrolled patients received no prior chemotherapy before surgeries. The surgically excised normal testis tissue was provided by a written-informed testicular cancer patient administrated at Affiliated Kunshan Hospital of Jiangsu University. Experiments and protocols requiring human tissues and cells were approved by the Ethics Board of Affiliated Kunshan Hospital of Jiangsu University, according to Declaration of Helsinki.

Cell culture

Ovarian cancer cell line CaOV3 was purchased from the Cell Bank of Shanghai Institute of Biological Science, CAS (Shanghai, China). Cells were cultured in the medium previously described14. The normal ovarian epithelial (“OE”) cells were provided by Dr. Bi14, which were cultured in MCDB109/M199 medium with 20% fetal bovine serum (FBS). The achieved ovarian cancer tissues were washed in phosphate-buffered saline for five times and minced into small pieces (1 mm3), which were digested by Collagenase I (Sigma-Aldrich) and DNase (Sigma-Aldrich). Single-cell suspensions were pelleted and washed in Dulbecco’s modified Eagle medium (DMEM). Fibroblasts, blood vessel cells, and immune cells were abandoned via mechanical means and centrifugation. Purified primary human ovarian cancer cells were cultured in the medium previously described15. Four different ovarian cancer cells were established, named “pOC-1/4”. All cells were regularly checked to exclude possible mycoplasma and microbial contamination. Authentication by STR profiling, population doubling time, and cell morphology were also routinely examined to verify the genotypes every 3–4 months.

qPCR

Trizol reagents (Promega, Madison, WI) were added for RNA extraction. A SYBR Green PCR kit (Applied Biosystems, Foster City, CA) was utilized for reverse transcription under the ABI Prism7500 Fast Real-Time PCR system. A melt curve analysis was performed to calculate product melting temperatures. To quantify targeted gene expression a 2−∆∆Ct method was applied, with GAPDH tested as the internal control. The primers were listed in Table 1.

Table 1.

Sequences utilized in this study.

qPCR primers
Genes Forward (5′–3′) Reverse (5′–3′)
BRDT AAGCCTCCTCTGAAGGGAACTC GGGACAAAACCTGGAGCTGTTG
PLK1 GCACAGTGTCAATGCCTCCAAG GCCGTACTTGTCCGAATAGTCC
AURKC CCACAGTGAGACTTACAGACGC GCTGGTATCTGAGAAGCCTGGA
GAPDH GTCTCCTCTGACTTCAACAGCG ACCACCCTGTTGCTGTAGCCAA
shRNA sequences (5′–3′)
 Scramble shRNA UAGCGACUAAACACAUCAATT
 BRDT shRNA-1 AAGACTTCAATACAATGTTCTCA
 BRDT shRNA-2 AAGATGAGCGAGTTAAGCGTCTT
 BRDT shRNA-3 AATAATGATGTCCAAAGAAGAAC
 PLK1 shRNA GTGCTTCGAGATCTCGGAC
 AURKC CCACGATAATAGAGGAGTTGGCAGATGCC
sgRNA sequences (5′–3′)
 BRDT sgRNA-1 TCTCCCTTGAACGTGGTACA (Target DNA Sequence)
 BRDT sgRNA-2 TCTCCCTTGAACGTGGTACA (Target DNA Sequence)
Open in a new tab

Western blotting

Cells or tissues were incubated with the described lysis buffer14. Aliquots of 40 µg of proteins of each condition were separated by 10% sodium dodecyl sulphate–polyacrylamide gel electrophoresis gels and then transferred to PVDF blots (Millipore, Bedford, MA). After blocking, blots were incubated with specific primary antibodies (overnight at 4 °C) and corresponding secondary antibodies (2 h at room temperature)14. Antibody-antigen bindings were tested by an enhanced chemiluminescence (ECL) system (Amersham Biosciences, Piscataway, NJ). An Image J software (NIH) was utilized for data quantification.

MTT assay

Cells, with different genetic manipulations, were initially seeded into 96-well plates at a density of 2.5 × 103 cells per well. After incubation for 72 h, the cell viability was tested by MTT assay. MTT optical density (OD) was measured at 550 nm.

BrdU assay

Ovarian cancer cells were seeded into 96-well plates at a density of 2.5 × 103 cells per well. Following incubation with BrdU (10 μM, Cell Signaling Tech, Shanghai, China) for 48 h, cells were washed and BrdU incorporation was tested by an ELISA kit (Cell Signaling Tech), with ELISA absorbance tested at 405 nm.

“Transwell” assay

Genetically modified CaOV3 cells (1.5 × 105 cells in 250 μL serum-free medium) were seeded into “Transwell” upper chambers (16-μm pore size, BD Biosciences, Shanghai, China). The lower compartments were filled with 10% FBS medium. After 24 h, the non-migrated cells on the upper surface were removed. The migrated cells, on the lower surface, were fixed, stained and counted.

Caspase-3 activity assay

Ovarian cancer cell lysates (20 μg of each treatment) were mixed with the described assay buffer16, together with the caspase-3 substrate (Ac-DEVD-AFC). Following extensive washes, the caspase-3 enzymatic AFC activity was measured at the excitation wavelength of 380 nm and the emission wavelength of 440 nm.

EdU staining

Ovarian cancer cells with applied genetic modifications were seeded into 24-well plates (3 × 104 cells per well) and cultured for 48 h. Next, an EdU (5-ethynyl-20-deoxyuridine) staining assay was performed using the described protocol elsewhere17,18. EdU percentages (EdU vs. DAPI, %) of 800 cells in five random views (per treatment, 1 × 100 magnification) were recorded.

Mitochondrial depolarization

JC-1 fluorescence dye can form green monomers by aggregating in the mitochondria in apoptotic cells with mitochondrial depolarization19. Ovarian cancer cells with applied genetic modifications were seeded into 24-well plates (3 × 104 cells per well) and cultured for 48 h. Cells were then stained with JC-1 (10 μg/mL, Sigma). JC-1 fluorescence images, integrating green (at 488 nm) and red (at 625 nm) wavelengths were presented. JC-1 green fluorescence intensity (at 488 nm) was recorded as well.

Short-hairpin RNA (shRNA)-mediated gene silencing

There different shRNAs, targeting non-overlapping sequences (“−1/−2/−3”, listed in Table 1) of BRDT, were individually sub-cloned into a GV248 (hU6-MCS-Ubiquitin-EGFP-IRES-puromycin) construct. The shRNA construct, along with the lentivirus package plasmids, were co-transfected to HEK-293 cells to generate BRDT shRNA lentivirus. Following filtration and enrichment, the virus was added to ovarian cancer cells (cultured in the polybrene medium, same for all virus procedures). The infected cells were then subjected to selection by puromycin (2.0 μg/mL) for another 4–5 passages. Knockdown of BRDT in the stable cells was verified by qPCR and Western blotting assays. Silencing of PLK1 and AURKC was through the same procedure, with their shRNA sequences listed in Table 1.

BRDT knockout

The single-guide RNA (sgRNA) targeting BRDT (two different sequences, “sgRNA-1/-2”, listed in Table 1, provided by Shanghai Genechem Co.) was sub-cloned into a lenti-CRISPR-GFP-puro construct, which was transfected to HEK-293 cells along with the lentivirus package plasmids to generate BRDT-KO virus. The virus was filtered, enriched and added to ovarian cancer cells for 24 h. Cells were subjected to selection with puromycin (2.0 μg/mL) for 4–5 passages. In the resulting stable cells BRDT KO was verified by western blotting and qPCR assays.

Overexpression of BRDT and others

The full-length BRDT cDNA was synthesized and sequence-verified by Shanghai Genechem Co, sub-cloned to a GV248 vector. The construct was then transfected to HEK-293 cells with the lentiviral packaging plasmids20, generating BRDT-expressing lentivirus (“LV-BRDT”). Following filtration and enrichment, LV-BRDT was added to ovarian cancer cells. Afterwards, puromycin (2.0 μg/mL) was included to select stable cells, where BRDT overexpression was verified by Western blotting and qPCR assays. Control cells were infected with lentivirus with empty vector (“LV-C”). Ectopic overexpression of PLK1 and AURKC was through the same protocol.

Xenograft assay

The severe combined immunodeficient (SCID) mice (17.5–18.5 g, 4–5-week-old) were obtained from the Animal Center of Chinese Academy of Science (Shanghai, China). CaOV3 or pOC-1 primary cells (for each mouse, 5 × 106 cells in 100 μL DMEM plus 100 μL Matrigel, no serum) were subcutaneously (s.c.) injected to the right flanks of SCID mice. After 3 weeks the subcutaneous xenografts were established (around 100 mm3), and recordings were initiated (Day-0, or “D0”). Mice body weights and bi-dimensional tumor measurements were recorded every seven days for total 35 days. The animal protocols were approved by the Ethics Board and IACUC of Affiliated Kunshan Hospital of Jiangsu University.

Statistical analyses

In vitro experiments were repeated at least three times and similar results were obtained. Values were normalized when necessary and expressed as mean ± standard deviation (SD, normal distribution). For statistical analyses the SPSS software (version 21.0, using one-way ANOVA) was employed. To test significance between two treatment groups, a two-tailed unpaired t-test (Excel 2007) was utilized. All differences were considered significant at P < 0.05.

Results

BRDT overexpression in ovarian cancer

First, the database proteomicsdb (www.proteomicsdb.org) was consulted to verify BRDT expression in human tissues. As shown, BRDT protein is primarily expressed in testis, lung and ovarian tissues (Fig. 1A), very few was detected in other human tissues. To verify the data, a total of six ovarian cancer tissues (“Ca”) and paired surrounding normal ovarian epithelial tissues (“S”) were tested. These tissues were derived from six different primary ovarian cancer patients: Pat-1 to Pat-6. The qPCR results, Fig. 1B, demonstrated that BRDT mRNA expression was relatively low in normal ovarian epithelial tissues (Fig. 1B), but was significantly upregulated in five out of six cancer tissues (Pat-1 to Pat-5, Fig. 1B). BRDT protein upregulation was detected as well in the five ovarian cancer tissues (Fig. 1C). Again, low BRDT protein expression was detected in ovarian epithelial tissues (Fig. 1C). BRDT expression in human testis tissue was shown as the positive control (Fig. 1B, C).

Fig. 1. BRDT overexpression in ovarian cancer.

Fig. 1

Open in a new tab

BRDT protein expression profile from the proteomicsdb database (A). BRDT mRNA and protein expression in the listed human ovarian cancer tissues (“Ca”) and para-cancer normal ovarian epithelial tissues (“S”), as well as in the listed ovarian cancer cells and ovarian epithelial (“OE”) cells was tested by qPCR (B and D) and Western blotting (C and E) assays. Each tissue was randomly cut into five different pieces (B). BRDT expression in human testis tissues was tested as the positive control (B–E). BRDT protein expression was quantified and normalized to Tubulin (C and E). For each assay, n = 5 (D). *P < 0.05 vs. “S” tissues (B) or “OE” cells (D). Experiments in this figure were repeated three times, with similar results obtained.

In established (CaOV3 cell line) and primary human ovarian cancer cells, BRDT mRNA (Fig. 1D) and protein (Fig. 1E) expression was significantly higher than that in ovarian epithelial (“OE”) cells. The primary cancer cells were derived from the four ovarian cancer tissues with significant BRDT upregulation (“Pat-1/-2/-3/-4”, see Fig. 1B, C). These results together show that BRDT is overexpressed in human ovarian cancer tissues and cells.

BRDT shRNA inhibits ovarian cancer cell survival, growth, proliferation, and migration

We tested whether BRDT played a role in the oncogenic behaviors of ovarian cancer cells. Three different BRDT shRNAs, with non-overlapping sequences (namely “shBRDT-1/-2/-3”, listed in Table 1), were individually transfected to CaOV3 cells. Following selection by puromycin, stable cells were established. Analyzing BRDT mRNA expression, by qPCR, demonstrated that BRDT mRNA levels were significantly decreased in stable cells with BRDT shRNA (Fig. 2A). BRDT protein levels were downregulated as well (Fig. 2A). Cell counting assay results, in Fig. 2B, demonstrated that stable CaOV3 cells with BRDT shRNA grew significantly slower than control cells (with scramble control shRNA/“shSCR”). BRDT knockdown in CaOV3 cells inhibited cell viability (MTT OD, Fig. 2C) and proliferation (BrdU incorporation, Fig. 2D). Furthermore, BRDT silencing potently decreased EdU-positive nuclei ratio in CaOV3 cells, further confirming proliferation inhibition (Fig. 2E). “Transwell” assay results, Fig. 2F, demonstrated that the applied BRDT shRNAs inhibited CaOV3 cell migration in vitro (Fig. 2F).

Fig. 2. BRDT shRNA inhibits ovarian cancer cell survival, growth, proliferation and migration.

Fig. 2

Open in a new tab

CaOV3 cells (A–F) or the primary human ovarian cancer cells (“pOC-1/-2/-3/-4”) (G–K) were transfected with scramble control shRNA lentivirus (“shSCR”) or the BRDT shRNA lentivirus (“shBRDT-1/-2/-3”, with different shRNA sequence) for 24 h, stable cells were selected by puromycin. BRDT mRNA or protein expression was shown (A and G); Cell growth (B), viability (MTT assay, C and H), as well as proliferation (BrdU ELISA and EdU staining assays, D, E, I and J), and cell migration (“Transwell” assays, F and K) were tested by the appropriate assays, results were quantified. For the functional assays, the exact same amount of viable cells with different genetic modifications were initially (at 0 h) seeded into each well/dish and cultured for applied time periods (same for all Figures). BRDT protein expression was quantified and normalized to Tubulin (A). For each assay, n = 5 (five dishes or wells). *P < 0.05 vs. “shSCR” cells. Experiments in this figure were repeated five times, with similar results obtained. Scale Bar = 100 μm (E and F).

To test BRDT’s function in primary cells, primary human ovarian cancer cells (“pOC-1/-2/-3/-4”, derived from different patients, see Fig. 1) were transfected with the lentiviral BRDT shRNA (“shBRDT-3”) as well. Stable cells were achieved by puromycin selection, showing significantly decreased BRDT mRNA expression (Fig. 2G). BRDT shRNA potently inhibited cell viability (MTT OD, Fig. 2H) and proliferation (BrdU ELISA OD, Fig. 2I) in primary cancer cells. Additionally, EdU-positive nuclei ratio was significantly decreased following BRDT silencing (Fig. 2J). Moreover, BRDT silencing inhibited in vitro migration of primary cancer cells (“Transwell” assays, Fig. 2K). Altogether, these results show that BRDT silencing exerted significant anti-ovarian cancer cell activity.

BRDT silencing provokes apoptosis activation in ovarian cancer cells

In ovarian cancer cells viability inhibition and growth arrest could induce apoptosis activation21,22. Next, we test whether BRDT silencing can induce apoptosis in ovarian cancer cells. We showed that BRDT silencing, by shBRDT-1/-2/-3 (see Fig. 2), significantly increased caspase-3 activity in CaOV3 cells (Fig. 3A). Cleavages of caspase-3, caspase-9 and PARP were detected in BRDT-silenced CaOV3 cells (Fig. 3B). Furthermore, BRDT shRNA-induced DNA breaks, which were evidenced by single strand DNA (ssDNA) accumulation (Fig. 3C). Additional experimental results showed that JC-1 green monomers were accumulated in BRDT-silenced CaOV3 cells, indicating mitochondrial depolarization19 (Fig. 3D). These results indicated activation of mitochondrial apoptosis pathway in BRDT-silenced CaOV3 cells23–26. In BRDT shRNA-expressing CaOV3 cells, apoptosis activation was further confirmed by increased number of apoptotic nuclei, showing condensed or fragmented nuclear Hoechst 33342 staining (Fig. 3E).The characteristic apoptotic nuclei were labeled with yellow stars (Fig. 3E), although only part of them were TUNEL-positive (purple fluorescence, Fig. 3E, same for all figures).

Fig. 3. BRDT silencing provokes apoptosis activation in ovarian cancer cells.

Fig. 3

Open in a new tab

CaOV3 cells (A–E) or the primary human ovarian cancer cells (“pOC-1/-2/-3/-4”) (F–H) were transfected with scramble control shRNA lentivirus (“shSCR”) or the BRDT shRNA lentivirus (“shBRDT-1/-2/-3”, with different shRNA sequence) for 24 h, stable cells were selected by puromycin; Cells were further cultured for applied time periods, caspase activation (A, B, and F), single strand DNA (ssDNA) contents (C), mitochondrial depolarization (JC-1 assay, D and G) were tested. Cell apoptosis was examined by and Hoechst 33342 nuclei staining assay (E and H). For each assay, n = 5 (five dishes or wells). *P < 0.05 vs. “shSCR” cells. Experiments in this figure were repeated five times, with similar results obtained. Scale Bar = 100 μm (D and E).

In the primary human ovarian cancer cells (“pOC-1/-2/-3/-4”), shBRDT-3-induced BRDT silencing (see Fig. 2) resulted in caspase-3 activity increase (Fig. 3F), mitochondrial depolarization (JC-1 green monomers accumulation, Fig. 3G) and apoptotic nuclei increase (Fig. 3H), confirming apoptosis activation. Collectively, these results show that BRDT silencing-induced apoptosis activation in ovarian cancer cells.

CRISPR/Cas9-induced BRDT knockout potently inhibits ovarian cancer cell progression

To further confirm the role of BRDT in ovarian cancer cells, we utilized the CRISPR/Cas9 strategy. As described, two lentiviral CRISPR/Cas9-BRDT-KO constructs, with different sgRNAs (“sgRNA-1/-2”), were individually transduced to CaOV3 cells. Following selection by puromycin stable cells were established. Analyzing BRDT mRNA and protein expression in the stable cells confirmed that BRDT was completely depleted by the CRISPR/Cas9 constructs (Fig. 4A). Significantly, in CaOV3 cells BRDT KO potently inhibited cell viability (MTT OD, Fig. 4B). BrdU incorporation (Fig. 4C) and EdU-positive nuclei ratio (Fig. 4D) were decreased in BRDT-KO CaOV3 cells, indicating proliferation inhibition. “Transwell” assay results, Fig. 4E, demonstrated that CaOV3 cell migration was largely inhibited with BRDT KO.

Fig. 4. CRISPR/Cas9-induced BRDT knockout potently inhibits ovarian cancer cell progression.

Fig. 4

Open in a new tab

CaOV3 cells (A–H) or the primary human ovarian cancer cells (“pOC-1/-2/-3/-4”) (I–K) were transfected with the CRISPR/Cas9-BRDT-KO constructs (with “sgRNA-1/-2”) or the CRISPR/Cas9-control construct (“Cas9-C”), with selection by the puromycin stable cells were established. BRDT mRNA or protein expression was shown (A and I); Cell viability (MTT OD, B and J) and proliferation (BrdU incorporation and EdU staining assays, C, D and K), as well as cell migration (“Transwell” assay, E) were tested. Caspase activation (F), single strand DNA (ssDNA) contents (G) as well as cell apoptosis (Hoechst 333342 staining, H) were tested. For each assay, n = 5 (five dishes or wells). *P < 0.05 vs. “Cas9-C” cells. Experiments in this figure were repeated three times, with similar results obtained. Scale Bar = 100 μm (D and E).

Additional studies demonstrated that CRISPR/Cas9-induced BRDT KO increased caspase-3 activity (Fig. 4F) and induced DNA breaks (ssDNA accumulation, Fig. 4G). Furthermore, significant apoptosis activation was detected in BRDT KO CaOV3 cells, evidenced by increased ratio of apoptotic nuclei (Fig. 4H).

In primary human ovarian cancer cells (“pOC-1/-2/-3/-4”), transfection of lentiviral CRISPR/Cas9-BRDT-KO construct (with “sgRNA-1”) depleted BRDT mRNA (Fig. 4I), thereby resulting in viability reduction (Fig. 4J) and proliferation inhibition (Fig. 4K). Therefore, similar to the shRNA results, BRDT KO potently inhibited ovarian cancer cell progression in vitro.

BRDT overexpression promotes ovarian cancer proliferation and migration

Based on these results, we hypothesized that forced BRDT overexpression might promote ovarian cancer cell growth. To test this hypothesis, a lentiviral BRDT expression construct (“LV-BRDT”) was transfected to CaOV3 cells. Puromycin was applied again to select two stable cell lines (“sL-1/sL-2”). Testing BRDT mRNA expression, by qPCR, confirmed that in the LV-BRDT stable cells BRDT mRNA levels increased over 10 folds (vs. control cells with empty vector/“LV-C”) (Fig. 5A). BRDT protein levels were increased as well (Fig. 5A). As shown, exogenous BRDT overexpression augmented CaOV3 cell viability (Fig. 5B) and proliferation (by recording EdU-positive nuclei ratio, Fig. 5C). BRDT overexpression also promoted CaOV3 cell migration, tested by “Transwell” assays (Fig. 5D) These results further confirmed that BRDT plays an essential role in ovarian cancer cell progression.

Fig. 5. BRDT overexpression promotes ovarian cancer proliferation and migration.

Fig. 5

Open in a new tab

CaOV3 cells were transfected with lentiviral BRDT expression construct (“LV-BRDT”) or the empty vector (“LV-C”), stable cells were selected by puromycin. BRDT mRNA and protein expression (A), cell viability (MTT OD, B), proliferation (by recording EdU-positive nuclei ratio, C) and migration (“Transwell” assays, D) were tested similarly. BRDT protein expression was quantified and normalized to Tubulin (A). For each assay, n = 5 (five dishes or wells). *P < 0.05 vs. “LV-C” cells. Experiments in this figure were repeated three times, with similar results obtained. Scale Bar = 100 μm (C and D).

BRDT depletion-induced anti-ovarian cancer cell activity is associated with PLK1-AURKC downregulation

It has been shown that BRDT is essential for the transcription and expression of PLK1 and AURKC11, both are important oncogenic or pro-cancerous genes13,21,27. In stable CaOV3 cells with BRDT-shRNA (“shBRDT-1/-2”, see Fig. 2) or CRISPR/Cas9-BRDT-KO construct (“sgRNA-1”, see Fig. 4), mRNA and protein expression of PLK1 and AURKC were significantly downregulated (Fig. 6A, B). Conversely, forced BRDT overexpression in CaOV3 cells (see Fig. 5) significantly increased PLK1 and AURKC expression (both mRNA and protein) (Fig. 6C, D). These results suggest that BRDT is indeed important for PLK1 and AURKC expression in ovarian cancer cells.

Fig. 6. BRDT depletion-induced anti-ovarian cancer cell activity is associated with PLK1-AURKC downregulation.

Fig. 6

Open in a new tab

The mRNA and protein expressions of listed genes in the stable CaOV3 cells, with the lentiviral BRDT shRNA (“shBRDT-1/-2”), the lentiviral CRISPR/Cas9-BRDT-KO construct (“sgRNA-1”), or the lentiviral BRDT expression construct (“LV-BRDT”), were tested by qPCR (A and C) and western blotting (B and D) assays. Stable CaOV3 cells expressing the CRISPR/Cas9-BRDT-KO construct (with “sgRNA-1”, “ko-BRDT” cells) were further transfected with or without lentivirus encoding PLK1 and AURKC (“ + lv-PLK1 + lv-AURKC”), control cells were with empty vector (“Vec”), expression of listed proteins was shown (E); Cells were further cultured for applied time periods, cell proliferation (recording EdU-positive nuclei ratio, F), mitochondrial depolarization (JC-1 green monomers intensity, G) and apoptosis (recording apoptotic nuclei ratio, H) were tested by the appropriate assays. CaOV3 cells were transfected with scramble control shRNA lentivirus (“shSCR”) or PLK1 shRNA lentivirus plus AURKC shRNA lentivirus (“PLK1 + AURKC D-shRNA”) for 24 h, stable cells were selected by puromycin. Expression of listed proteins was shown (I). Cells were further cultured for applied time periods, cell proliferation (J) and apoptosis (K) were tested by EdU staining and apoptotic nuclei staining assays, respectively. For each assay, n = 5 (five dishes or wells). *P < 0.05 vs. “shSCR”/“Vec” cells. #P < 0.05. Expression of listed proteins was quantified and normalized to Tubulin. Experiments in this figure were repeated three times, with similar results obtained. Scale Bar = 100 μm (J and K).

To test the link between BRDT depletion-induced anti-ovarian cancer cell activity and PLK1-AURKC downregulation, BRDT-KO CaOV3 cells were further transfected with lentivirus encoding PLK1 and AURKC (“ + lv-PLK1 + lv-AURKC”). Stable cells were established with puromycin selection. As shown PLK1 and AURKC protein expression was restored by the two constructs in BRDT-KO CaOV3 cells (Fig. 6E). Functional studies demonstrated that BRDT-KO-induced proliferation inhibition (EdU ratio decrease, Fig. 6F), mitochondrial depolarization (JC-1 green intensity increase, Fig. 6G) and cell apoptosis (increased apoptotic nuclei ratio, Fig. 6H) were largely attenuated with PLK1 and AURKC re-expression (Fig. 6F–H). Thus, PLK1-AURKC downregulation should be a primary mechanism of BRDT depletion-induced anti-ovarian cancer cell activity. However, single overexpression of PLK1 or AURKC only slightly attenuated BRDT-KO-induced proliferation inhibition (Fig. S1A) and apoptosis activation (Fig. S1B) in CaOV3 cells. Single overexpression-induced rescue effect in the ko-BRDT cells was significantly weaker than double overexpression (Fig. 6F–H).

To further support our hypothesis, CaOV3 cells were co-transfected with lentivirus encoding PLK1 shRNA and AURKC shRNA. Stable cells were again achieved: namely “PLK1 + AURKC D-shRNA” cells. As shown PLK1 and AURKC protein expression was significantly downregulated in CaOV3 cells with “PLK1 + AURKC D-shRNA” (Fig. 6I), where significant proliferation inhibition (decreased nuclear EdU ratio, Fig. 6J) and apoptosis (Fig. 6K) were detected.

Notably, shRNA-induced single knockdown of PLK1 or AURKC only slightly induced proliferation inhibition (by recording EdU-positive nuclei ratio, Fig. S1C) and apoptosis activation (Fig. S1D). Importantly, PLK1 plus AURKC double knockdown (“D-shRNA”)-induced anti-CaOV3 cell activity was stronger than single knockdown (Fig. S1C, D), but was weaker than BRDT KO (Fig. S1C, D). These results implied that other protein targets, besides PLK1 or AURKC, should also participate in BRDT-mediated ovarian cancer cell progression. qPCR assay results, Figure S1E, demonstrated expression of targeted mRNAs in CaOV3 cells with applied genetic modifications.

BRDT silencing inhibits ovarian cancer xenograft growth in SCID mice

In order to study the potential effect of BRDT in ovarian cancer cell growth in vivo, control CaOV3 cells (“Cas9-C”) and BRDT-KO (with “sgRNA-1”) CaOV3 cells were inoculated to SCID mice to form subcutaneous xenografts. Tumor growth curve results, Fig. 7A, demonstrated that xenografts-derived from BRDT-KO CaOV3 cells grew significantly slower than the control tumors (formed by Cas9-C cells). By calculating the estimated daily tumor growth, using the formula [tumor volume at Day-35 (D35) subtracting tumor volume at Day-0 (D0)]/35, we show that BRDT-KO CaOV3 tumor growth was significantly inhibited (Fig. 7B). At D35 tumors of the two groups were isolated and weighted. As demonstrated, BRDT-KO CaOV3 xenografts were significantly lighter than the control tumors (Fig. 7C). The mice body weights, on the other hand, were not significantly different between the two groups (Fig. 7D). There were no noticeable signs of apparent toxicity. These results suggest that BRDT-KO significantly inhibited CaOV3 cell growth in vivo.

Fig. 7. BRDT silencing inhibits ovarian cancer xenograft growth in SCID mice.

Fig. 7

Open in a new tab

The SCID mice were injected s.c. with control and BRDT-KO CaOV3 cells (5 × 106 cells in 100 μL DMEM plus 100 μL Matrigel, no serum) at the right flanks, within 3 weeks the xenografts were established (Day-0, “D0”). The tumor volumes (A) and mice body weights (B) were recorded every seven days for total 35 days; The estimated daily tumor growth was calculated (C); At D35 all tumors were isolated and weighted (D). At D7 three tumors of each group were isolated and tissues lysates were subjected to Western blotting assays of listed proteins (E). The SCID mice were injected s.c. with pOC-1 primary ovarian cancer cells (5 × 106 cells in 100 μL DMEM plus 100 μL Matrigel, no serum) at the right flanks. Within 3 weeks the xenografts were established (Day-0, “D0”). The mice were then subjected to intratumoral injection of either BRDT shRNA lentivirus (“shBRDT-3”) or control shRNA lentivirus (shSCR). Thereafter, the tumor volumes (F) and mice body weights (G) were recorded every 7 days; At Day-7/D7, two tumors of each group were isolated and tissues lysates were subjected to Western blotting assays (H). Listed protein expression was quantified and normalized to Tubulin (E and H). n = 8 mice per group *P < 0.05 vs. “Cas9-C”/“shSCR” tumors.

To testing signaling changes, at D7, three tumors of each group were isolated and tissues lysates were analyzed for signaling proteins. As shown, BRDT was depleted in BRDT-KO CaOV3 xenografts (Fig. 7E), where PLK1 and AURKC expression was significantly decreased (Fig. 7E). These signaling results in vivo are in line with the in vitro findings.

To further support the role of BRDT in ovarian cancer cell growth in vivo, primary ovarian cancer cells, pOC-1, were s.c. injected to the flanks of SCID mice, forming pOC-1 xenografts within 3 weeks. The mice were then randomly assigned into two groups, receiving intratumoral injection of either BRDT shRNA lentivirus (“shBRDT-3”) or control shRNA lentivirus (shSCR). When recording tumor growth, we found that shBRDT-3 injection potently inhibited pOC-1 xenograft growth in mice (Fig. 7F), but without affecting mice body weights (Fig. 7G). At Day-7 (D7), two tumors of each group were isolated and tissues lysates were subjected to Western blotting assays. Results confirmed BRDT silencing in shBRDT-3-injected tumors (Fig. 7H), with PLK1 and AURKC downregulation observed (Fig. 7H). These results further indicated that BRDT is important for ovarian cancer cell growth in vivo.

Discussion

BRDT is a driver of meiotic and post-meiotic gene expression6,28. BRDT binds to acetylated lysines to regulate epigenetic processes, essential for chromatin structure formation in mitosis progression6. Furthermore, BRDT recruits positive transcription elongation factor b (p-TEFb), regulating transcription elongation and expression of several key proteins6, including PLK1 and AURKC11. A threefold higher BRDT expression is detected in adult testis than that in the embryo testis29,30. BRDT expression is correlated with histone H4 hyperacetylation during spermiogenesis29,30. In patient with abnormal spermatogenesis, few or no BRDT expression is detected in testis29,30. Recent studies have shown that BRDT is reactivated and expressed in various human cancers, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinomas (HNSCC) and esophagus squamous cell carcinomas, but not in melanoma or in cancers of the colon, breast, kidney and bladder6,28,30. The proteomicsdb database and our results in human tissues confirmed that BRDT is expressed in ovarian tissues.

Our results here suggest that BRDT is possibly one important oncogenic gene and therapeutic target of ovarian cancer. Its expression is significantly upregulated in ovarian cancer tissues and in established (CaOV3)/primary human ovarian cancer cells. Low BRDT expression, however, is detected in ovarian epithelial tissues and cells. In ovarian cancer cells, BRDT shRNA or CRISPR-Cas9-indueced BRDT knockout potently inhibited cell growth, survival, proliferation and migration, whereas inducing apoptosis activation. Conversely, forced BRDT overexpression augmented CaOV3 cell proliferation and migration. Importantly, BRDT-KO CaOV3 xenograft tumors grew significantly slower than the control tumors. Furthermore, intratumoral injection of BRDT shRNA lentivirus potently inhibited pOS-1 xenograft growth in SCID mice. These results suggest that targeting BRDT could be a novel and efficient strategy to inhibit ovarian cancer cells, in vitro and in vivo.

PLK1 plays an essential role in regulating cell cycle progression12. It is required for a number of cell cycle processes, including cell mitotic entry and G2/M checkpoint, centrosome coordination, spindle assembly and chromosome segregation12. PLK1 also exerts key functions at the spindle midzone during abscission, facilitating DNA replication and cytokinesis12. It is, therefore, vital for cell cycle progression and cell proliferation12. Studies have indicated an oncogenic activity of overexpressed PLK1 in ovarian cancer21,27, that is important for cancer cell progression and chemoresistance21,27. Additionally, AURKC, another BRDT-regulated gene, is reactivated and overexpressed in multiple different human cancer cells13, essential for cancerous behaviors, including cell proliferation and migration13. AURKC could promote xenograft tumor growth13. Kinase-dead AURKC inhibited HeLa cell proliferation, whereas constitutively active AURKC promoted cancer cell progression31–33.

The results of the current study show that PLK1 and AURKC are expressed in ovarian cancer cells. Significantly, the two were downregulated by BRDT shRNA or KO, but being upregulated with ectopic BRDT overexpression. PLK1 and AURKC downregulation was also detected in BRDT-KO CaOV3 tumor tissues and in pOS-1 xenografts with BRDT shRNA injection. Importantly, BRDT-KO-induced anti-ovarian cancer cell activity was largely attenuated with PLK1 and AURKC re-expression. PLK1 plus AURKC double silencing-induced proliferation inhibition and apoptosis activation in CaOV3 cells, mimicking BRDT silencing-induced actions. Therefore, BRDT-mediated ovarian cancer cell progression is associated with regulation of PLK1 and AURKC expression. The detailed mechanisms may warrant further characterizations.

Conclusion

The current treatments for ovarian cancer, with combination of platinum-based chemotherapy and surgery, can only result in a 5-year overall survival close to 45%. It goes down to 25% for the advanced cancers34. The poor survival highlights the limitations in the biological understanding of this devastating disease35–38. It is, therefore, urgent to indentify novel therapeutic strategies/molecular targets35–38. Recent genomic studies have demonstrated the extensive alternations of epigenetic regulators in ovarian cancers, which might be utilized as basis for developing new epigenetic drugs35–38. Our results indicate that BRDT overexpression promotes ovarian cancer cell progression in vitro and in vivo. Targeting BRDT could be a novel strategy to treat ovarian cancer.

Supplementary information

Supplementary Figure 1 (318.9KB, pdf)

Acknowledgements

This work was generously supported by grants from Natural Science Foundation of China (81902715), Natural Science Foundation of Jiangsu Province (BK20180195) and Scientific Research Program for Young Talents of China National Nuclear Corporation (Shang Cai, 51003) by Jiangsu Young Medical Talents (Grant No. QNRC2016180), and Six Talent Peaks Project of Jiangsu Province (WSN-173). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Footnotes

Edited by S. Tait

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Ling Chen, Shang Cai

Contributor Information

Pei-Hua Lu, Email: lphty1_1@163.com.

Qian Chu, Email: drqianchuob@hotmail.com.

Supplementary information

Supplementary Information accompanies this paper at (10.1038/s41419-020-03225-y).

References

  • 1.Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J. Clin. 2009;59:27–41. doi: 10.3322/caac.20008. [DOI] [PubMed] [Google Scholar]
  • 2.Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017;67:7–30. doi: 10.3322/caac.21387. [DOI] [PubMed] [Google Scholar]
  • 3.Matulonis UA, et al. Ovarian cancer. Nat. Rev. Dis. Prim. 2016;2:16061. doi: 10.1038/nrdp.2016.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Nielsen FC, van Overeem Hansen T, Sorensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat. Rev. Cancer. 2016;16:599–612. doi: 10.1038/nrc.2016.72. [DOI] [PubMed] [Google Scholar]
  • 5.Groen RS, Gershenson DM, Fader AN. Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all. Gynecol. Oncol. 2015;136:373–383. doi: 10.1016/j.ygyno.2014.11.078. [DOI] [PubMed] [Google Scholar]
  • 6.Bourova-Flin E, Chuffart F, Rousseaux S, Khochbin S. The role of bromodomain testis-specific factor, BRDT, in cancer: a biomarker and a possible therapeutic target. Cell J. 2017;19:1–8. doi: 10.22074/cellj.2017.5060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Fensterle J, Aicher B, Seipelt I, Teifel M, Engel J. Current view on the mechanism of action of perifosine in cancer. Anticancer Agents Med. Chem. 2014;14:629–635. doi: 10.2174/1871520614666140309225912. [DOI] [PubMed] [Google Scholar]
  • 8.Radin NS. Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come? Eur. J. Biochem. 2001;268:193–204. doi: 10.1046/j.1432-1033.2001.01845.x. [DOI] [PubMed] [Google Scholar]
  • 9.Fu LL, et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget. 2015;6:5501–5516. doi: 10.18632/oncotarget.3551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell. 2014;54:728–736. doi: 10.1016/j.molcel.2014.05.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Matzuk MM, et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012;150:673–684. doi: 10.1016/j.cell.2012.06.045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Liu Z, Sun Q, Wang X. PLK1, a potential target for cancer therapy. Transl. Oncol. 2017;10:22–32. doi: 10.1016/j.tranon.2016.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Quartuccio SM, Schindler K. Functions of aurora kinase C in meiosis and cancer. Front. Cell Dev. Biol. 2015;3:50. doi: 10.3389/fcell.2015.00050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Yang YL, et al. Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells. Cancer Sci. 2012;103:1538–1545. doi: 10.1111/j.1349-7006.2012.02335.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Minjie S, Defei H, Zhimin H, Weiding W, Yuhua Z. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595. Tumour Biol. 2015;36:9015–9022. doi: 10.1007/s13277-015-3537-5. [DOI] [PubMed] [Google Scholar]
  • 16.Lv H, et al. Preclinical evaluation of liposomal C8 ceramide as a potent anti-hepatocellular carcinoma agent. PLoS ONE. 2016;11:e0145195. doi: 10.1371/journal.pone.0145195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wang SS, et al. Triptonide inhibits human nasopharyngeal carcinoma cell growth via disrupting Lnc-RNA THOR-IGF2BP1 signaling. Cancer Lett. 2019;443:13–24. doi: 10.1016/j.canlet.2018.11.028. [DOI] [PubMed] [Google Scholar]
  • 18.Yang L, et al. C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study. Exp. Cell Res. 2015;332:47–59. doi: 10.1016/j.yexcr.2014.12.017. [DOI] [PubMed] [Google Scholar]
  • 19.Brooks MM, Neelam S, Fudala R, Gryczynski I, Cammarata PR. Lenticular mitoprotection. Part A: monitoring mitochondrial depolarization with JC-1 and artifactual fluorescence by the glycogen synthase kinase-3beta inhibitor, SB216763. Mol. Vis. 2013;19:1406–1412. [PMC free article] [PubMed] [Google Scholar]
  • 20.Zhang X, et al. microRNA-9 selectively targets LMX1A to promote gastric cancer cell progression. Biochem. Biophys. Res. Commun. 2018;505:405–412. doi: 10.1016/j.bbrc.2018.09.101. [DOI] [PubMed] [Google Scholar]
  • 21.Guo P, Xiong X, Zhang S, Peng D. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Oncol. Rep. 2016;36:3552–3558. doi: 10.3892/or.2016.5140. [DOI] [PubMed] [Google Scholar]
  • 22.Zhang D, Xia H, Zhang W, Fang B. The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor. Tumour Biol. 2016;37:1327–1336. doi: 10.1007/s13277-015-3922-0. [DOI] [PubMed] [Google Scholar]
  • 23.Fu M, Shi W, Li Z, Liu H. Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 2016;477:527–533. doi: 10.1016/j.bbrc.2016.04.147. [DOI] [PubMed] [Google Scholar]
  • 24.Fu M, Wan F, Li Z, Zhang F. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 2016;471:267–273. doi: 10.1016/j.bbrc.2016.01.030. [DOI] [PubMed] [Google Scholar]
  • 25.Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99–104. doi: 10.1038/sj.cdd.4400476. [DOI] [PubMed] [Google Scholar]
  • 26.Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 2004;5:897–907. doi: 10.1038/nrm1496. [DOI] [PubMed] [Google Scholar]
  • 27.Chan KK, et al. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma. Int. J. Cancer. 2018;143:1456–1469. doi: 10.1002/ijc.31535. [DOI] [PubMed] [Google Scholar]
  • 28.Scanlan MJ, et al. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett. 2000;150:155–164. doi: 10.1016/S0304-3835(99)00385-7. [DOI] [PubMed] [Google Scholar]
  • 29.Jones MH, Numata M, Shimane M. Identification and characterization of BRDT: A testis-specific gene related to the bromodomain genes RING3 and Drosophila fsh. Genomics. 1997;45:529–534. doi: 10.1006/geno.1997.5000. [DOI] [PubMed] [Google Scholar]
  • 30.Zheng Y, Yuan W, Zhou Z, Xu M, Sha JH. Molecular cloning and expression of a novel alternative splice variant of BRDT gene. Int. J. Mol. Med. 2005;15:315–321. [PubMed] [Google Scholar]
  • 31.Khan J, et al. Overexpression of active Aurora-C kinase results in cell transformation and tumour formation. PLoS ONE. 2011;6:e26512. doi: 10.1371/journal.pone.0026512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Tsou JH, et al. Aberrantly expressed AURKC enhances the transformation and tumourigenicity of epithelial cells. J. Pathol. 2011;225:243–254. doi: 10.1002/path.2934. [DOI] [PubMed] [Google Scholar]
  • 33.Spengler D. Aurora-C-T191D is a hyperactive aurora-C mutant. Cell Cycle. 2007;6:1803–1804. doi: 10.4161/cc.6.14.4479. [DOI] [PubMed] [Google Scholar]
  • 34.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. [DOI] [PubMed] [Google Scholar]
  • 35.Nick AM, Coleman RL, Ramirez PT, Sood AK. A framework for a personalized surgical approach to ovarian cancer. Nat. Rev. Clin. Oncol. 2015;12:239–245. doi: 10.1038/nrclinonc.2015.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Markman M. Chemotherapy: limited use of the intraperitoneal route for ovarian cancer-why? Nat. Rev. Clin. Oncol. 2015;12:628–630. doi: 10.1038/nrclinonc.2015.177. [DOI] [PubMed] [Google Scholar]
  • 37.Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat. Rev. Clin. Oncol. 2013;10:211–224. doi: 10.1038/nrclinonc.2013.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Vaughan S, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer. 2011;11:719–725. doi: 10.1038/nrc3144. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure 1 (318.9KB, pdf)

Articles from Cell Death & Disease are provided here courtesy of Nature Publishing Group

RESOURCES